Resources

Standard Operating Procedure: Whole blood specimens will be characterized for intracellular G6PD activity by flow cytometry, allowing observation of mosaic red blood cell populations in specimens from females by looking at G6PD activity in individual erythrocytes.

Standard Operating Procedure: The Trinity Biotech Glucose-6 Phosphate Dehydrogenase assay kit is used for the quantitative, spectrophotometric determination of G6PD activity in human blood samples.

Standard Operating Procedure: The Pointe Scientific Glucose-6 Phosphate Dehydrogenase (G6PD) assay kit is used for the quantitative, spectrophotometric determination of G6PD activity in human blood samples.

Progress toward elimination of onchocerciasis, or river blindness, is the result of decades of dedication to controlling this disease. Over the past few years, mass drug administration of ivermectin has moved the goal from control to elimination. As programs work toward this, they need appropriate diagnostic tools to identify exposure to Onchocerca volvulus (Ov) to detect possible recrudescence. PATH and its partners have developed a rapid diagnostic test (RDT) that detects immunoglobulin G4-related disaease (IgG4) antibodies specific to Ov16 and it will be manufactured by Standard Diagnostics, Inc. (SD). Prior to availability, its performance was evaluated in a series of assessments in both lab and field settings.

This document reviews the steps to organize how processes and information and communication technology infrastructure can be integrated and standardized to meet a ministry of health’s vision and requirements to increase vaccination coverage for under-reached populations. It combines a top-down approach with a bottom-up view—beginning with national strategies while incorporating current user context and health-facility applications. Find out more about PATH's work in digital health solutions.